C Ray Therapeutics, a Chengdu, China-based enterprise in the field of radiopharmaceuticals, raised over $100M in Series A+ funding.
The round was led by Shenzhen Capital Group Co., Ltd.’s Manufacturing Transformation and Upgrading New Materials Fund and TaiLong Capital, with participation from GL Ventures, 3SBio (01530.HK), Guanghua Wutong, and a well-known industrial investment institution.
The company intends to use the funds to expand operations and its development efforts.
Established in 2021, C Ray Therapeutics has been dedicated to the field of radiopharmaceuticals. Within just over three years, the company has achieved a series of landmark accomplishments:
- Establishing a platform with advanced global equipment, technology innovation, and comprehensive functional support in the field of radiopharmaceuticals.
- Construction of a nearly 30,000 square meter R&D and production base for radiopharmaceuticals.
- Obtaining the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise.
Utilizing its R&D and production facilities, C Ray offers one-stop customized services to partners. These include:
– Providing CRO services and companion diagnostic development for conventional drugs using molecular imaging.
– Offering validation services for the druggability of new targets in innovative drug development.
– Delivering end-to-end CRDMO services for radiopharmaceuticals, from early discovery and PCC verification through IND filing, clinical supply, and commercial production.
FinSMEs
18/11/2024